Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12027MR)

This product GTTS-WQ12027MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12027MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3058MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ3290MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ5924MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ12962MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ469MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ3757MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ9373MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ4172MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW